Article | Published:

Life extension through neurofibromin mitochondrial regulation and antioxidant therapy for neurofibromatosis-1 in Drosophila melanogaster

Nature Genetics volume 39, pages 476485 (2007) | Download Citation

Subjects

Abstract

We investigated the pathophysiology of neurofibromatosis-1 (NF1) in Drosophila melanogaster by inactivation or overexpression of the NF1 gene. NF1 gene mutants had shortened life spans and increased vulnerability to heat and oxidative stress in association with reduced mitochondrial respiration and elevated reactive oxygen species (ROS) production. Flies overexpressing NF1 had increased life spans, improved reproductive fitness, increased resistance to oxidative and heat stress in association with increased mitochondrial respiration and a 60% reduction in ROS production. These phenotypic effects proved to be modulated by the adenylyl cyclase/cyclic AMP (cAMP)/protein kinase A pathway, not the Ras/Raf pathway. Treatment of wild-type D. melanogaster with cAMP analogs increased their life span, and treatment of NF1 mutants with metalloporphyrin catalytic antioxidant compounds restored their life span. Thus, neurofibromin regulates longevity and stress resistance through cAMP regulation of mitochondrial respiration and ROS production, and NF1 may be treatable using catalytic antioxidants.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Malignancy in neurofibromatosis type 1. Oncologist 5, 477–485 (2000).

  2. 2.

    Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89, 1–6 (1999).

  3. 3.

    & Recent advances in neurofibromatosis type 1. Curr. Opin. Neurol. 17, 101–105 (2004).

  4. 4.

    , , , & A circadian output in Drosophila mediated by neurofibromatosis-1 and Ras/MAPK. Science 293, 2251–2256 (2001).

  5. 5.

    & Ras/Raf/ERK signalling and NF1. Cell Cycle 3, 1255–1258 (2004).

  6. 6.

    , , , & A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature 403, 895–898 (2000).

  7. 7.

    , , , & Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5, 95–96 (2002).

  8. 8.

    et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276, 791–794 (1997).

  9. 9.

    The genetic and molecular pathogenesis of NF1 and NF2. Semin. Pediatr. Neurol. 13, 21–26 (2006).

  10. 10.

    , , , & Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276, 795–798 (1997).

  11. 11.

    , & Synaptic plasticity in Drosophila memory and hyperexcitable mutants: role of cAMP cascade. J. Neurosci. 12, 644–651 (1992).

  12. 12.

    & Paraquat: model for oxidant-initiated toxicity. Environ. Health Perspect. 55, 37–46 (1984).

  13. 13.

    A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359–407 (2005).

  14. 14.

    , , & Selectivity of protein oxidative damage during aging in Drosophila melanogaster. Biochem. J. 360, 209–216 (2001).

  15. 15.

    , & Oxidative damage during aging targets mitochondrial aconitase. Proc. Natl. Acad. Sci. USA [published erratum appears in Proc. Natl. Acad. Sci. USA 1998 Feb 17;95(4):1968] 94, 11168–11172 (1997).

  16. 16.

    , , & A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J. Pharmacol. Exp. Ther. 275, 1227–1232 (1995).

  17. 17.

    , , , & Flavin-dependent antioxidant properties of a new series of meso-N,N'-dialkyl-imidazolium substituted manganese(III) porphyrins. Biochem. Pharmacol. 67, 77–85 (2004).

  18. 18.

    & Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol. Sci. 20, 359–364 (1999).

  19. 19.

    Catalytic antioxidants: a radical approach to new therapeutics. Drug Discov. Today 9, 557–566 (2004).

  20. 20.

    et al. Extension of Drosophila life span by overexpression of human SOD1 in motorneurons. Nat. Genet. 19, 171–174 (1998).

  21. 21.

    , & Targeted neuronal gene expression and longevity in Drosophila. Exp. Gerontol. 35, 1157–1164 (2000).

  22. 22.

    Pleiotropy, natural selection, and the evoluton of senescence. Evolution Int. J. Org. Evolution 11, 398–411 (1957).

  23. 23.

    & Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 263, 1128–1130 (1994).

  24. 24.

    , , & Induced overexpression of mitochondrial Mn-superoxide dismutase extends the life span of adult Drosophila melanogaster. Genetics 161, 661–672 (2002).

  25. 25.

    , & Effects of simultaneous over-expression of Cu/ZnSOD and MnSOD on Drosophila melanogaster life span. Mech. Ageing Dev. 125, 341–349 (2004).

  26. 26.

    et al. The effects of exogenous antioxidants on life span and oxidative stress resistance in Drosophila melanogaster. Mech. Ageing Dev. 127, 356–370 (2006).

  27. 27.

    , , & Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. J. Neurochem. 78, 746–755 (2001).

  28. 28.

    et al. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol. Appl. Pharmacol. 199, 10–19 (2004).

  29. 29.

    , , , & Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52, 642–649 (2003).

  30. 30.

    et al. High resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO. Physiol. Genomics, published online 7 November 2006 (doi:10.1152/physiolgenomics.00061.2006).

  31. 31.

    et al. Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry 40, 13941–13947 (2001).

  32. 32.

    , , & The phosphorylation of subunits of complex I from bovine heart mitochondria. J. Biol. Chem. 279, 26036–26045 (2004).

  33. 33.

    et al. Phosphorylation of B14.5a subunit from bovine heart complex I identified by titanium dioxide selective enrichment and shotgun proteomics. Mol. Cell Proteomics 6, 231–237 (2006).

  34. 34.

    et al. Regulation by the cAMP cascade of oxygen free radical balance in mammalian cells. Antioxid. Redox Signal. 8, 495–502 (2006).

  35. 35.

    et al. Complex I and the cAMP cascade in human physiopathology. Biosci. Rep. 22, 3–16 (2002).

  36. 36.

    et al. cAMP controls oxygen metabolism in mammalian cells. FEBS Lett. 580, 4539–4543 (2006).

  37. 37.

    et al. Somatic mitochondrial DNA mutations in neurofibromatosis type 1-associated tumors. Mol. Cancer Res. 2, 433–441 (2004).

  38. 38.

    et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. USA 102, 719–724 (2005).

  39. 39.

    , & Mitochondrial mutations in cancer. Oncogene 25, 4647–4662 (2006).

  40. 40.

    Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 18, 775–794 (1995).

  41. 41.

    In vivo and in organello assessment of OXPHOS activities. Methods 26, 307–316 (2002).

  42. 42.

    et al. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J. Biol. Chem. 273, 28510–28515 (1998).

  43. 43.

    & Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 44, 276–287 (1971).

  44. 44.

    & A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem. 195, 133–140 (1952).

Download references

Acknowledgements

We thank S. Summers, J. Nguyen, M. Holmbeck and A. Skejsol for their technical assistance. We also thank V. Caiozzo, V. Procaccio, L. Mueller, V. Subramaniam, K. Waymire, M. Kernan, E. Ruiz-Pesini, A. Flierl, G. McGregor, P. Coskun, S. Gaffey and M. T. Lott for their comments and help. We thank J. Williams (New Jersey Medical and Dental School) for the UAS-dNF1 transgenic lines. This work was supported by the Ellison New Opportunity Award, by a US National Institutes of Health (NIH) multidisciplinary exercise fellowship (AR-47752) and Grass Foundation fellowship awards for 2004 and 2006 to J.J.T. and by an Ellison Foundation Senior Investigator Award and NIH grants AG13154, AG24373, AG01751, DK73691, NS21328 and NS41850 awarded to D.C.W.

Author information

Affiliations

  1. Center for Molecular and Mitochondrial Medicine and Genetics with Departments of Biological Chemistry, Ecology and Evolutionary Biology and Pediatrics University of California, Irvine, California 92697, USA.

    • James Jiayuan Tong
    • , Samuel E Schriner
    • , David McCleary
    •  & Douglas C Wallace
  2. Multidisciplinary Exercise Program, Biophysics and Physiology, University of California, Irvine, California 92697, USA.

    • James Jiayuan Tong
  3. National Jewish Medical Research Center, Denver, Colorado 80206, USA.

    • Brian J Day

Authors

  1. Search for James Jiayuan Tong in:

  2. Search for Samuel E Schriner in:

  3. Search for David McCleary in:

  4. Search for Brian J Day in:

  5. Search for Douglas C Wallace in:

Contributions

J.J.T. produced Figures 1,2,3,4,5,6,–7 and Supplementary Figures 1, 2, 3b, 4, 5, 6, and 7a, prepared the manuscript and contributed to the revisions and correspondence during the review process. S.E.S. produced Supplementary Figures 3a and 7b and contributed to the manuscript revision. D.M. contributed to Figures 4a–c and 5 and Supplementary Figure 4c. B.J.D. provided MnTDEIP. D.C.W. supervised, managed and funded the research and revised and finalized the manuscript.

Competing interests

B.J.D. is a consultant for and holds equity in Aeolus Pharmaceutical, which is commercially developing porphyrins as therapeutic agents.

Corresponding author

Correspondence to Douglas C Wallace.

Supplementary information

PDF files

  1. 1.

    Supplementary Fig. 1

    Normal desiccation tolerance in NF1 mutants.

  2. 2.

    Supplementary Fig. 2

    NF1/AC/cAMP signaling modulated mitochondrial respiration.

  3. 3.

    Supplementary Fig. 3

    Intact oxidative stress defense enzymes in NF1 mutants.

  4. 4.

    Supplementary Fig. 4

    Life extension correlated with NF1 expression level.

  5. 5.

    Supplementary Fig. 5

    Life extension in Drosophila melanogaster by neuronal NF1 overexpression.

  6. 6.

    Supplementary Fig. 6

    Elevated cAMP in NF1-overexpressing flies and cAMP feeding did not alter fly body weights.

  7. 7.

    Supplementary Fig. 7

    NF1 expression did not alter dephosphorylated FOXO or MnSOD levels.

  8. 8.

    Supplementary Table 1

    Gompertz parameters of NF1-overexpressing flies.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ng2004

Further reading